Lifecare is developing an implantable continuous glucose sensor based on its proprietary osmotic pressure cell technology. Late April-19 Lifecare reported that our nanosensor technology has been shown in laboratory experiments to accurately measure pressure changes derived from substantially smaller osmotic pressure chambers than previously available.
Results by 30.06.19 confirms that we have achieved further miniaturizing based on the actual results in line with budgets and strategies set forth in the Oslo Børs Merkur admission document. The Norwegian Research Council has also confirmed funding of NOK 425.000,- to support our development program.
Lifecare will therefore continue downsizing the core glucose-sensing element of our device with the smallest pressure sensor of the world, which will ultimately lead to significant competitive advantages for the final product.